Next-Generation Polymyxin Class of Antibiotics: A Ray of Hope Illuminating a Dark Road

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2022 Dec 23

PMID 36551367

Authors

Abdullah Tarik Aslan

Murat Akova

David L Paterson

Affiliations

Soon will be listed here.

Abstract

Although new-generation antimicrobials, in particular β-lactam/β-lactamase inhibitors, have largely replaced polymyxins in carbapenem-resistant Gram-negative bacterial infections, polymyxins are still needed for carbapanem-resistant infections and in settings where novel agents are not readily available. Despite their potent in vitro activity, the clinical utility of polymyxins is significantly limited by their pharmacokinetic properties and nephrotoxicity risk. There is significant interest, therefore, in developing next-generation polymyxins with activity against colistin-resistant strains and lower toxicity than existing polymyxins. In this review, we aim to present the antibacterial activity mechanisms, in vitro and in vivo efficacy data, and toxicity profiles of new-generation polymyxins, including SPR206, MRX-8, and QPX9003, as well as the general characteristics of old polymyxins. Considering the emergence of colistin-resistant strains particularly in endemic regions, the restoration of the antimicrobial activity of polymyxins via PBT2 is also described in this review.

Citing Articles

Nanoformulation of Polymyxin E Through Complex Coacervation: A Pharmacokinetic Analysis.

Chen X, Liu L, Wang W, Yuan Y, Wang W Pharmaceutics. 2025; 17(1).

PMID: 39861724 PMC: 11769286. DOI: 10.3390/pharmaceutics17010076.

Thanatin and vinyl sulfide analogues as narrow spectrum antimicrobial peptides that synergise with polymyxin B.

Shepperson O, Harris P, Brimble M, Cameron A Front Pharmacol. 2024; 15:1487338.

PMID: 39564120 PMC: 11573584. DOI: 10.3389/fphar.2024.1487338.

The challenges of difficult-to-treat infections.

Richards G, Perovic O, Brink A Clin Microbiol Rev. 2024; 37(4):e0009324.

PMID: 39555919 PMC: 11629631. DOI: 10.1128/cmr.00093-24.

Pharmacokinetics and Nephrotoxicity of Polymyxin MRX-8 in Rats: A Novel Agent against Resistant Gram-Negative Bacteria.

Qu X, Guo C, Liu S, Li X, Xi L, Liu X Antibiotics (Basel). 2024; 13(4).

PMID: 38667030 PMC: 11047535. DOI: 10.3390/antibiotics13040354.

: an evolving and cunning opponent.

Shi J, Cheng J, Liu S, Zhu Y, Zhu M Front Microbiol. 2024; 15:1332108.

PMID: 38318341 PMC: 10838990. DOI: 10.3389/fmicb.2024.1332108.

References

Brown P, Dawson M . Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections. J Antibiot (Tokyo). 2017; 70(4):386-394. DOI: 10.1038/ja.2016.146. View

Manchandani P, Thamlikitkul V, Dubrovskaya Y, Babic J, Lye D, Lee L . Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2017; 104(3):534-538. DOI: 10.1002/cpt.981. View

Falagas M, Kasiakou S . Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005; 40(9):1333-41. DOI: 10.1086/429323. View

Wu S, Yin D, Zhi P, Guo Y, Yang Y, Zhu D . Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China. Front Cell Infect Microbiol. 2022; 12:829592. PMC: 9135056. DOI: 10.3389/fcimb.2022.829592. View

Yu Z, Qin W, Lin J, Fang S, Qiu J . Antibacterial mechanisms of polymyxin and bacterial resistance. Biomed Res Int. 2015; 2015:679109. PMC: 4312571. DOI: 10.1155/2015/679109. View

Nation R, Garonzik S, Thamlikitkul V, Giamarellos-Bourboulis E, Forrest A, Paterson D . Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2016; 64(5):565-571. PMC: 5850520. DOI: 10.1093/cid/ciw839. View

Li J, Nation R, Milne R, Turnidge J, Coulthard K . Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2004; 25(1):11-25. DOI: 10.1016/j.ijantimicag.2004.10.001. View

Garonzik S, Li J, Thamlikitkul V, Paterson D, Shoham S, Jacob J . Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011; 55(7):3284-94. PMC: 3122440. DOI: 10.1128/AAC.01733-10. View

Ahmad Gogry F, Siddiqui M, Sultan I, Haq Q . Current Update on Intrinsic and Acquired Colistin Resistance Mechanisms in Bacteria. Front Med (Lausanne). 2021; 8:677720. PMC: 8406936. DOI: 10.3389/fmed.2021.677720. View

10.

Aggarwal R, Dewan A . Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study. Ann Clin Microbiol Antimicrob. 2018; 17(1):15. PMC: 5865377. DOI: 10.1186/s12941-018-0262-0. View

11.

Kamel N, Elsayed K, Awad M, Aboshanab K, El Borhamy M . Multimodal Interventions to Prevent and Control Carbapenem-Resistant Enterobacteriaceae and Extended-Spectrum β-Lactamase Producer-Associated Infections at a Tertiary Care Hospital in Egypt. Antibiotics (Basel). 2021; 10(5). PMC: 8146387. DOI: 10.3390/antibiotics10050509. View

12.

Gregoire N, Mimoz O, Megarbane B, Comets E, Chatelier D, Lasocki S . New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother. 2014; 58(12):7324-30. PMC: 4249546. DOI: 10.1128/AAC.03508-14. View

13.

Akhoundsadegh N, Belanger C, Hancock R . Outer Membrane Interaction Kinetics of New Polymyxin B Analogs in Gram-Negative Bacilli. Antimicrob Agents Chemother. 2019; 63(10). PMC: 6761527. DOI: 10.1128/AAC.00935-19. View

14.

Doremus C, Marcella S, Cai B, Echols R . Utilization of Colistin Versus β-Lactam and β-Lactamase Inhibitor Agents in Relation to Acute Kidney Injury in Patients with Severe Gram-Negative Infections. Infect Dis Ther. 2021; 11(1):187-199. PMC: 8564277. DOI: 10.1007/s40121-021-00556-x. View

15.

Rigatto M, Behle T, Falci D, Freitas T, Lopes N, Nunes M . Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother. 2015; 70(5):1552-7. DOI: 10.1093/jac/dku561. View

16.

Linden P, Kusne S, Coley K, Fontes P, Kramer D, Paterson D . Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2003; 37(11):e154-60. DOI: 10.1086/379611. View

17.

Roberts J, Lipman J . Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009; 37(3):840-51. DOI: 10.1097/CCM.0b013e3181961bff. View

18.

De Oliveira D, Bohlmann L, Conroy T, Jen F, Everest-Dass A, Hansford K . Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis. Sci Transl Med. 2020; 12(570). DOI: 10.1126/scitranslmed.abb3791. View

19.

Vaara M . Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics. Front Microbiol. 2019; 10:1689. PMC: 6671869. DOI: 10.3389/fmicb.2019.01689. View

20.

Gallardo-Godoy A, Hansford K, Muldoon C, Becker B, Elliott A, Huang J . Structure-Function Studies of Polymyxin B Lipononapeptides. Molecules. 2019; 24(3). PMC: 6384738. DOI: 10.3390/molecules24030553. View